In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme

Journal of Antimicrobial Chemotherapy

Volumn 73, Issue 7, 2018, Pages 1872-1879

  Karlowsky, James A ^a   Lob, Sibylle H ^b   Kazmierczak, Krystyna M ^b   Hawser, Stephen P ^c   Magnet, Sophie ^c   Young, Katherine ^d   Motyl, Mary R ^d   Sahm, Daniel F ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Division of Microbiology   (United States)

^c International Health Management Associates Europe Sàrl   (Switzerland)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZTREONAM; BETA LACTAMASE; CARBAPENEMASE; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; RELEBACTAM; ANTIINFECTIVE AGENT; AZABICYCLO DERIVATIVE; BACTERIAL PROTEIN; BETA LACTAMASE INHIBITOR; MK-7655;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; CLINICAL ARTICLE; CLINICAL EVALUATION; CONCENTRATION PROCESS; CONTROLLED STUDY; DISEASE SURVEILLANCE; ENTEROBACTER; HOSPITAL LABORATORY; HUMAN; IN VITRO STUDY; INFECTIOUS AGENT; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; PSEUDOMONAS AERUGINOSA; DRUG EFFECT; ENZYMOLOGY; EUROPE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; SENTINEL SURVEILLANCE;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BACTERIAL PROTEINS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; ENTEROBACTER; EUROPE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; SENTINEL SURVEILLANCE;

EID: 85050235059     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dky107     Document Type: Article

References (29)

1. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 2008; 197: 1079-81
2. Pogue JM, Kaye KS, Cohen DA et al. Appropriate antimicrobial therapy in the era of multidrug-resistant human pathogens. Clin Microbiol Infect 2015; 21: 302-12
3. Mauldin PD, Salgado CD, Hansen IS et al. Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant Gram-negative bacteria. Antimicrob Agents Chemother 2010; 54: 109-15
4. Bodro M, SabéN, Tubau F et al. Risk factors and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients. Transplantation 2013; 96: 843-9
5. Rice LB. Progress and challenges in implementing the research on ESKAPE pathogens. Infect Control Hosp Epidemiol 2010; 31 Suppl 1: S7-10
6. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12
7. Tam VH, Rogers CA, Chang KT et al. Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother 2010; 54: 3717-22
8. Patel TW, Nagel JL. Clinical outcomes of Enterobacteriaceae infections stratified by carbapenemMICs. JClinMicrobiol 2015; 53: 201-5
9. CDC. Antibiotic Resistance Threats in the United States, 2013. www. cdc. gov/drugresistance/pdf/ar-threats-2013-508. pdf
10. Van Boeckel TP, Gandra S, Ashok A et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis 2014; 14: 742-50
11. Toussaint KA, Gallagher JC. b-Lactam/b-lactamase inhibitor combinations: from then to now. Ann Pharmacother 2015; 49: 86-98
12. Drawz SM, Papp-Wallace KM, Bonomo RA. New b-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother 2014; 58: 1835-46
13. Jacoby GA. AmpCb-lactamases. ClinMicrobiol Rev 2009; 22: 161-82
14. Livermore DM, Warner M, Mushtaq S. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. JAntimicrobChemother 2013; 68: 2286-90
15. Young K, Raghoobar SL, Hairston NN et al. In vitro activity of the class A and C b-lactamase inhibitor MK-7655. In: Posters of the Fiftieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, USA, 2010. Poster F1-2139. American Society for Microbiology, Washington, DC, USA
16. Lapuebla A, Abdallah M, Olafisoye O et al. Activity of imipenemwith relebactam against Gram-negative pathogens from New York City. Antimicrob Agents Chemother 2015; 59: 5029-31
17. Olsen I. New promising b-lactamase inhibitors for clinical use. Eur J Clin Microbiol Infect Dis 2015; 34: 1303-8
18. Morrissey I, Hackel M, Badal R et al. A review of ten years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011. Pharmaceuticals (Basel) 2013; 6: 1335-46
19. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Tenth Edition: Approved Standard M07-A10. CLSI, Wayne, PA, USA, 2015
20. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Sixth Informational Supplement M100-S26. CLSI, Wayne, PA, USA, 2016
21. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 6. 0 (Valid From 2016-01-01). http://www. eucast. org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_6. 0_Breakpoint_table. pdf
22. Lob SH, Kazmierczak KM, Badal RE et al. Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013 Antimicrob Agents Chemother 2015; 59: 3606-10
23. Nichols WW, de Jonge BL, Kazmierczak KM et al. In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to ceftazidimeavibactam (INFORM 2012 to 2014). Antimicrob Agents Chemother 2016; 60: 4743-9
24. Winkler M, Hujer AM, Bethel CR et al. Imipenem-cilastatin-relebactam (IMI/REL): an analysis of resistance in Pseudomonas aeruginosa (Pa) isolates. In: Posters of the Fifty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA, 2015. Poster C-147. American Society forMicrobiology, Washington, DC, USA
25. Young K, Motyl M, Tatosian D. Effect of imipenem-relebactam on sub-types of KPC in Klebsiella pneumoniae. Open Forum Infectious Diseases 2016; 3 Suppl 1: 2005
26. Young K, Motyl M. Retrospective analysis of the effect of MK-7655 (relebactam) on imipenem non-susceptible Pseudomonas aeruginosa and KPC-expressing Enterobacteriaceae. In: Posters of the Fifty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA, 2015. Poster C-156. American Society for Microbiology, Washington, DC, USA
27. Queenan AM, Bush K. Carbapenemases: the versatile b-lactamases. Clin Microbiol Rev 2007; 20: 440-58
28. Lob SH, Hoban DJ, Sahm DF et al. Regional differences and trends in antimicrobial susceptibility of Acinetobacter baumannii. Int J Antimicrob Agents 2016; 47: 317-23
29. ClinicalTrials. gov. https://clinicaltrials. gov/ct2/results?term'MK-7655&Se arch'Search